Free Trial

Biomea Fusion (BMEA) Competitors

Biomea Fusion logo
$1.88 -0.03 (-1.57%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$1.92 +0.04 (+2.13%)
As of 07/17/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMEA vs. SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, ZYBT, CRDF, MREO, and KOD

Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

Biomea Fusion vs. Its Competitors

Sagimet Biosciences (NASDAQ:SGMT) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Sagimet Biosciences' return on equity of -35.21% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Sagimet BiosciencesN/A -35.21% -34.09%
Biomea Fusion N/A -197.71%-134.84%

In the previous week, Biomea Fusion had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Biomea Fusion and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.33 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sagimet Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biomea Fusion
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Sagimet Biosciences has higher revenue and earnings than Biomea Fusion. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sagimet Biosciences$2M146.45-$45.57M-$1.76-5.43
Biomea FusionN/AN/A-$138.43M-$3.55-0.53

Sagimet Biosciences has a beta of 3.35, indicating that its share price is 235% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 18.4% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sagimet Biosciences presently has a consensus target price of $26.60, indicating a potential upside of 178.53%. Biomea Fusion has a consensus target price of $20.10, indicating a potential upside of 969.15%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Sagimet Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biomea Fusion
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.18

Summary

Biomea Fusion beats Sagimet Biosciences on 8 of the 15 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMEA vs. The Competition

MetricBiomea FusionMED IndustryMedical SectorNASDAQ Exchange
Market Cap$71.76M$2.94B$5.57B$9.34B
Dividend YieldN/A2.45%3.80%4.06%
P/E Ratio-0.5320.2928.1019.86
Price / SalesN/A302.32441.4199.96
Price / CashN/A43.1635.8457.94
Price / Book1.327.838.265.67
Net Income-$138.43M-$55.11M$3.24B$257.80M
7 Day Performance-6.00%3.21%1.48%1.87%
1 Month Performance-1.57%12.86%8.07%10.92%
1 Year Performance-63.57%5.06%30.29%18.51%

Biomea Fusion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMEA
Biomea Fusion
3.2974 of 5 stars
$1.88
-1.6%
$20.10
+969.1%
-64.7%$71.76MN/A-0.5350Analyst Forecast
SGMT
Sagimet Biosciences
2.3509 of 5 stars
$9.46
-0.1%
$26.60
+181.2%
+180.9%$290.14M$2M-5.388
DBVT
DBV Technologies
3.858 of 5 stars
$10.58
-2.1%
$14.75
+39.5%
+142.8%$289.68M$4.15M-2.1580Positive News
ANNX
Annexon
2.2533 of 5 stars
$2.61
+1.2%
$12.50
+378.9%
-60.1%$286.34MN/A-2.2160
AVTE
Aerovate Therapeutics
N/A$9.82
-6.7%
N/A-86.7%$284.63MN/A-3.2820High Trading Volume
ALLO
Allogene Therapeutics
3.6656 of 5 stars
$1.29
+0.8%
$8.44
+554.6%
-63.7%$282.16M$20K-1.05310News Coverage
Positive News
TVRD
Tvardi Therapeutics
N/A$29.83
+9.1%
$64.25
+115.4%
N/A$279.21M$7.14M0.0080Analyst Forecast
Analyst Revision
High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.87
-0.3%
N/AN/A$276.86M$186.36M0.00278News Coverage
Positive News
CRDF
Cardiff Oncology
1.1796 of 5 stars
$4.13
+1.5%
$11.70
+183.3%
+75.2%$274.77M$680K-4.4920
MREO
Mereo BioPharma Group
1.5948 of 5 stars
$1.72
+6.8%
$7.20
+318.6%
-54.2%$273.48M$10M-24.5740High Trading Volume
KOD
Kodiak Sciences
3.967 of 5 stars
$5.17
+14.1%
$9.00
+74.1%
+72.4%$272.77MN/A-1.4290

Related Companies and Tools


This page (NASDAQ:BMEA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners